Roche
2023
The pharmaceutical industry is one of Germany’s most important export industries. In recent years, the export of pharmaceutical products has seen above-average growth compared to the other export sectors. In addition, research and development play a prominent role for pharmaceutical companies.
Our new study for Roche focuses on these two aspects. It examines the extent to which the German pharmaceutical industry is particularly value-added intensive and innovative in its exports.
Compared to those in the other industries, German pharmaceutical exports are characterised by above-average value-added intensity and growth dynamics. This means that the export of pharmaceutical products (for example, worth one million euros) is linked to more domestic value added and jobs than the average German export of one million euros.
In an international comparison, the German pharmaceutical industry is shown to be one of the most important players on the world market and has been able to maintain its share of world exports in recent years.
In terms of research, the German pharmaceutical industry is losing ground on its international competitors:
For this detailed investigation of the German pharmaceutical industry in a national and international comparison, we relied on the available statistical data. This was then analysed with the help of the Prognos model landscape.
To the study (PDF in German)
Further information, in German (Roche website)
Project team: Dr Georg Klose, Dr Andreas Sachs, Johann Weiss
Latest update: 07.12.2023
Senior Project Manager
Prognos supports the German Federal Environment Agency in underpinning the National Circular Economy Strategy with concrete measures, priorities and a robust monitoring system.
On behalf of the BMWE, we evaluate the impact of the BEG in the funding period 2021 – 2025 together with ifeu, ITG, and FIW.
Europe has a strong research capabilities, but too little market success. The European Innovation Act aims to change this, remove structural barriers and thereby significantly strengthen innovation in the EU. Prognos and its partners are assisting with its development.
On behalf of the Federal Ministry for the Environment, Prognos compiled the Green Tech Atlas 2025. The atlas provides a comprehensive overview of the cross-sectional environmental technology and resource efficiency industries.
Medical technology, pharmaceuticals, biotechnology and digital health solutions can reduce costs in the healthcare system and thus contribute to the financial stabilisation of statutory health insurance. Our study for the BDI shows just how high the potential is.
The Talent Booster Mechanism supports eleven EU regions that are suffering from a decline in the working-age population and a low proportion of university graduates. The first pillar has been successfully implemented.
A shrinking workforce, digitalisation and decarbonisation: Prognos examined the specific effects of global trends on regional labour markets.
The results of the OVERLAP project show that demographic changes, digital transformation and the need for a green transition are simultaneously affecting regions across the EU.
In recent years, Europe has maintained its strong position in the global market for clean energy technologies, but faces growing competition. On behalf of the European Commission, we examined the competitiveness of these technologies.
Germany needs around 166,000 additional full-time places for primary school children by the summer. We are examining how this can be achieved for the Federal Ministry of Education.
We combine economic research and strategy consulting for sustainable decisions in politics, business and society. Our robust data, precise analyses and scientifically based findings enable fact-based progress – financially independent, politically neutral.
